Lorcaserin (previously apd-356), a highly selective 5ht2c receptor agonist, is used for the treatment of obesity it has been shown to reduce body weight and food intake in animal models of obesity, and it is thought that targeting the 5ht2c receptor may alter body weight by regulating satiety lorcaserin is marketed as a salt form called belviq, which is lorcaserin hydrochloride. Belviq moa. Lorcaserin (belviq) is a us-approved weight loss agent lorcaserin (10mg tablet twice daily) was approved in 2012 and a slow release preparation ( belviq xr , 20 mg once daily) was approved in july and launched in october 2016 27 lorcaserin reduces food intake, possibly via suppressing appetite and increasing satiety, but the exact mechanism.
belviq moa
Lorcaserin (belviq) is a drug that promotes weight loss by affecting the brain's hypothalamus people taking lorcaserin eat less and feel fuller side effects, drug interactions, and use during pregnancy should be reviewed prior to taking any medication. Based on the mechanism of action of belviq and the theoretical potential for serotonin syndrome, use with extreme caution in combination with other drugs that may affect the serotonergic neurotransmitter systems, including, but not limited to, triptans, monoamine oxidase inhibitors (maois, including linezolid, an antibiotic which is a. Mechanism of action of lorcaserin: suppressing the appetite and increasing the satiety. helping to reduce the food intake..
Comments
Post a Comment